Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor

Research output: Contribution to journalShort survey

20 Citations (Scopus)

Abstract

A major focus of current research on the nicotinic acetylcholine receptor (AChR) has been to understand the molecular mechanism of ion channel inhibition. In particular, we put special emphasis on the description of the localization of the agonist self-inhibitory binding site. Binding of agonist in the millimolar concentration range to this particular site produces inhibition of the ion flux activity previously elicited by the same agonist at micromolar concentrations. Due to the similitude in the pharmacological and electrophysiological behavior in inhibiting the ion channel of both high agonist concentrations and noncompetitive antagonists, we first describe the localization of noncompetitive inhibitor binding sites on the AChR. There is a great body of experimental evidence for the existence and location of luminal high-affinity noncompetitive inhibitor binding sites. In this regard, the most simple mechanism to describe the action of noncompetitive inhibitors which bind to luminal sites and, by its semblance, the agonist self- inhibition itself, is based on the assumption that these compounds enter the open channel, bind to different rings within the M2 transmembrane domain of the receptor, and block cation flux by occluding the receptor pore. However, the existence of high-affinity nonluminal noncompetitive inhibitor binding sites is not consistent with the open-channel-blocking mechanism. Instead, the presence of the quinacrine locus at the lipid-protein (αM1) interface ~7 Å from the lipid-water interface and the ethidium domain located ~46 Å from the membrane surface in the wall of the vestibule open the possibility for the regulation of cation permeation by an allosteric process. Additionally, the observed (at least partially) overlapping between the quinacrine and the agonist self-inhibitory binding site also suggests an allosteric process for agonist self-inhibition. For this alternative mechanism, cholinergic agonist molecules first need to be partitioned into (or to be adsorbed onto) the lipid membrane to further interact with its binding site located at the lipid-protein interface.

Original languageEnglish
Pages (from-to)97-105
Number of pages9
JournalJournal of Neuroscience Research
Volume44
Issue number2
DOIs
StatePublished - 13 May 1996
Externally publishedYes

Fingerprint

Nicotinic Receptors
Binding Sites
Quinacrine
Ion Channels
Lipids
Cations
Cholinergic Agonists
Ethidium
Cholinergic Receptors
Membrane Lipids
Proteins
Pharmacology
Ions
Membranes
Water
Research

Keywords

  • agonist self-inhibitory binding site
  • localization of binding sites
  • luminal and nonluminal binding sites
  • nicotinic acetylcholine receptor
  • noncompetitive inhibitors

Cite this

@article{12239b9641c242c081b6c2853b1be145,
title = "Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor",
abstract = "A major focus of current research on the nicotinic acetylcholine receptor (AChR) has been to understand the molecular mechanism of ion channel inhibition. In particular, we put special emphasis on the description of the localization of the agonist self-inhibitory binding site. Binding of agonist in the millimolar concentration range to this particular site produces inhibition of the ion flux activity previously elicited by the same agonist at micromolar concentrations. Due to the similitude in the pharmacological and electrophysiological behavior in inhibiting the ion channel of both high agonist concentrations and noncompetitive antagonists, we first describe the localization of noncompetitive inhibitor binding sites on the AChR. There is a great body of experimental evidence for the existence and location of luminal high-affinity noncompetitive inhibitor binding sites. In this regard, the most simple mechanism to describe the action of noncompetitive inhibitors which bind to luminal sites and, by its semblance, the agonist self- inhibition itself, is based on the assumption that these compounds enter the open channel, bind to different rings within the M2 transmembrane domain of the receptor, and block cation flux by occluding the receptor pore. However, the existence of high-affinity nonluminal noncompetitive inhibitor binding sites is not consistent with the open-channel-blocking mechanism. Instead, the presence of the quinacrine locus at the lipid-protein (αM1) interface ~7 {\AA} from the lipid-water interface and the ethidium domain located ~46 {\AA} from the membrane surface in the wall of the vestibule open the possibility for the regulation of cation permeation by an allosteric process. Additionally, the observed (at least partially) overlapping between the quinacrine and the agonist self-inhibitory binding site also suggests an allosteric process for agonist self-inhibition. For this alternative mechanism, cholinergic agonist molecules first need to be partitioned into (or to be adsorbed onto) the lipid membrane to further interact with its binding site located at the lipid-protein interface.",
keywords = "agonist self-inhibitory binding site, localization of binding sites, luminal and nonluminal binding sites, nicotinic acetylcholine receptor, noncompetitive inhibitors",
author = "Arias, {H. R.}",
year = "1996",
month = "5",
day = "13",
doi = "10.1002/(SICI)1097-4547(19960415)44:2<97::AID-JNR1>3.0.CO;2-B",
language = "English",
volume = "44",
pages = "97--105",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor. / Arias, H. R.

In: Journal of Neuroscience Research, Vol. 44, No. 2, 13.05.1996, p. 97-105.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor

AU - Arias, H. R.

PY - 1996/5/13

Y1 - 1996/5/13

N2 - A major focus of current research on the nicotinic acetylcholine receptor (AChR) has been to understand the molecular mechanism of ion channel inhibition. In particular, we put special emphasis on the description of the localization of the agonist self-inhibitory binding site. Binding of agonist in the millimolar concentration range to this particular site produces inhibition of the ion flux activity previously elicited by the same agonist at micromolar concentrations. Due to the similitude in the pharmacological and electrophysiological behavior in inhibiting the ion channel of both high agonist concentrations and noncompetitive antagonists, we first describe the localization of noncompetitive inhibitor binding sites on the AChR. There is a great body of experimental evidence for the existence and location of luminal high-affinity noncompetitive inhibitor binding sites. In this regard, the most simple mechanism to describe the action of noncompetitive inhibitors which bind to luminal sites and, by its semblance, the agonist self- inhibition itself, is based on the assumption that these compounds enter the open channel, bind to different rings within the M2 transmembrane domain of the receptor, and block cation flux by occluding the receptor pore. However, the existence of high-affinity nonluminal noncompetitive inhibitor binding sites is not consistent with the open-channel-blocking mechanism. Instead, the presence of the quinacrine locus at the lipid-protein (αM1) interface ~7 Å from the lipid-water interface and the ethidium domain located ~46 Å from the membrane surface in the wall of the vestibule open the possibility for the regulation of cation permeation by an allosteric process. Additionally, the observed (at least partially) overlapping between the quinacrine and the agonist self-inhibitory binding site also suggests an allosteric process for agonist self-inhibition. For this alternative mechanism, cholinergic agonist molecules first need to be partitioned into (or to be adsorbed onto) the lipid membrane to further interact with its binding site located at the lipid-protein interface.

AB - A major focus of current research on the nicotinic acetylcholine receptor (AChR) has been to understand the molecular mechanism of ion channel inhibition. In particular, we put special emphasis on the description of the localization of the agonist self-inhibitory binding site. Binding of agonist in the millimolar concentration range to this particular site produces inhibition of the ion flux activity previously elicited by the same agonist at micromolar concentrations. Due to the similitude in the pharmacological and electrophysiological behavior in inhibiting the ion channel of both high agonist concentrations and noncompetitive antagonists, we first describe the localization of noncompetitive inhibitor binding sites on the AChR. There is a great body of experimental evidence for the existence and location of luminal high-affinity noncompetitive inhibitor binding sites. In this regard, the most simple mechanism to describe the action of noncompetitive inhibitors which bind to luminal sites and, by its semblance, the agonist self- inhibition itself, is based on the assumption that these compounds enter the open channel, bind to different rings within the M2 transmembrane domain of the receptor, and block cation flux by occluding the receptor pore. However, the existence of high-affinity nonluminal noncompetitive inhibitor binding sites is not consistent with the open-channel-blocking mechanism. Instead, the presence of the quinacrine locus at the lipid-protein (αM1) interface ~7 Å from the lipid-water interface and the ethidium domain located ~46 Å from the membrane surface in the wall of the vestibule open the possibility for the regulation of cation permeation by an allosteric process. Additionally, the observed (at least partially) overlapping between the quinacrine and the agonist self-inhibitory binding site also suggests an allosteric process for agonist self-inhibition. For this alternative mechanism, cholinergic agonist molecules first need to be partitioned into (or to be adsorbed onto) the lipid membrane to further interact with its binding site located at the lipid-protein interface.

KW - agonist self-inhibitory binding site

KW - localization of binding sites

KW - luminal and nonluminal binding sites

KW - nicotinic acetylcholine receptor

KW - noncompetitive inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0029863212&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-4547(19960415)44:2<97::AID-JNR1>3.0.CO;2-B

DO - 10.1002/(SICI)1097-4547(19960415)44:2<97::AID-JNR1>3.0.CO;2-B

M3 - Short survey

C2 - 8723217

AN - SCOPUS:0029863212

VL - 44

SP - 97

EP - 105

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 2

ER -